跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
WEGOVY
Authorized
STANDARD
WEGOVY
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c8c413dfe44e5e0c
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
c8c413dfe44e5e0c
Drug Approval Canada Name
WEGOVY
Product Name
WEGOVY
Status
Marketed
Status Date
2024-03-28
Original Market Date
2024-03-28
Din
02528509
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
68:20.06
Atc Original
A10BJ06 SEMAGLUTIDE
Atc Name
a 10 bj 06
Aig Number
0159870010
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
SEMAGLUTIDE
1 MG / 1.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c8c413dfe44e5e0c
Type
Standard
Back to Health Canada Approvals
WEGOVY - Health Canada Drug Approval Details